These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21951605)

  • 1. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
    Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
    Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.
    Kageyama S; Ikeda H; Miyahara Y; Imai N; Ishihara M; Saito K; Sugino S; Ueda S; Ishikawa T; Kokura S; Naota H; Ohishi K; Shiraishi T; Inoue N; Tanabe M; Kidokoro T; Yoshioka H; Tomura D; Nukaya I; Mineno J; Takesako K; Katayama N; Shiku H
    Clin Cancer Res; 2015 May; 21(10):2268-77. PubMed ID: 25855804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
    Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
    Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
    Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
    Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
    Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
    Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
    Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
    Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
    Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
    Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
    Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
    J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.